Daily briefing

Medicare proposes making Advantage prior authorizations go electronic

Nov 21, 2026

Illustration: a white rural mailbox on a post with a glowing cable plugged into the slot of its front door.

Medicare Advantage plans would have to require in-network clinicians to submit prior authorization requests through a standardized electronic interface under a rule the Centers for Medicare & Medicaid Services proposed Nov. 20.

The contract year 2028 rule would also guarantee patients 90 days of in-network coverage when a clinician leaves a plan's network, shrink Star Ratings to 15 measures and launch a mandatory 10-year Advantage model in randomly chosen states in 2029, according to CMS. In California, Tahoe Forest Health System said an employee uploaded emergency patients' diagnoses and record numbers to ChatGPT. Johnson & Johnson's Ottava surgical robot entered commercial use in Houston, and FDA rejected a Duchenne muscular dystrophy cell therapy over data integrity violations.

  • WatchRegulation Nov 20, 2026

    Comments are due 60 days after the rule is published in the Federal Register, CMS said.

    PracticesHospitals
    The Centers for Medicare & Medicaid Services on Nov. 20 proposed that Medicare Advantage contracts require in-network providers to send prior authorization requests and documentation through each plan's FHIR-based Prior Authorization application programming interface, a standardized electronic connection, and that plans test every in-network provider's ability to use it once a year, according to the agency's fact sheet. The contract year 2028 rule would also require plans to keep covering a terminated provider's services for affected enrollees at in-network rates and cost sharing for at least 90 days, and would treat a termination as a significant network change when it affects at least 10% of a plan's enrollees or of its contracted network for a specialty. It would cut the Star Ratings measure set to 15 measures focused on clinical outcomes and patient experience. A companion request for information asks about expanding primary care networks and using what the agency called "Super Intelligence (also called Artificial Intelligence)," according to the press release.
  • WatchRegulation Nov 20, 2026

    A pre-implementation period begins June 8, 2027, and the 10-year test starts in 2029, CMS said.

    Practices
    The same proposed rule creates ADVaNCE MA, which CMS described as the Innovation Center's first mandatory Medicare Advantage model, a 10-year test in randomly selected states beginning in calendar year 2029. In those states a localized, cohort-based Diamond Ratings System would replace Star Ratings and quality bonus payments, and the agency would shadow-test a new risk adjustment model built on traditional Medicare claims and Advantage encounter data, according to the fact sheet. The model would also target supplemental benefits such as healthy food, transportation and caregiver support to low-income enrollees. Separately, the rule would require food sold through Advantage supplemental benefits to meet the 2025-2030 Dietary Guidelines for Americans unless a clinician recommends an item for an enrollee's medical needs.
  • FYIIncident Nov 20, 2026
    Hospitals
    Tahoe Forest Health System in Truckee, Calif., is notifying patients that an employee uploaded identifiable health information to ChatGPT to analyze data, a breach the system said it learned of on Sept. 18. The uploaded fields included last names, first initials, ages, sex, medical record numbers, chief complaints, emergency department diagnoses and acuity, arrival and discharge times, and the first emergency department provider, according to the system's statement. The system said it has restricted AI platforms on its network, added staff training, reported the breach to the California Department of Public Health and HHS, and is working with ChatGPT representatives on whether the data can be removed. It has not said how many patients were affected, Becker's Hospital Review reported.
  • FYIDeployment Nov 20, 2026
    Memorial Hermann-Texas Medical Center became the first hospital to commercially install and use Ottava, Johnson & Johnson's soft tissue surgical robot, under the company's early access program, MedTech Dive reported Nov. 20. FDA granted the system De Novo authorization in July 2026 for 10 upper-abdominal general surgery procedures, including cholecystectomy, Roux-en-Y gastric bypass, sleeve gastrectomy, appendectomy and hiatal hernia repair. Its four arms are built into a standard-sized operating table, and the company said it will keep the launch to select U.S. customers while it evaluates more indications. The installation follows the Nov. 17 clearance of Medtronic's Hugo robot for upper-abdominal general surgery.
    Source: MedTech Dive
  • FYIRegulation Nov 20, 2026
    FDA issued a complete response letter on Nov. 20 declining to approve deramiocel, Capricor Therapeutics' allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy, citing "serious data integrity violations" in the HOPE-3 study that the agency said cannot be fixed after the fact. An FDA inspection found unauthorized post hoc changes to the statistical analysis plan, blinding violations and other protocol violations, and the study missed its prespecified primary and secondary endpoints, the agency said. Capricor had changed the proposed indication from cardiomyopathy to upper limb impairment and filed 24-month open-label extension data after a July 29 advisory committee meeting. "The agency cannot approve a product on the basis of data whose reliability has been compromised," FDA said.
    Source: FDA
  • FYIMoney Nov 20, 2026
    Primary care
    HHS on Nov. 20 announced $47 million in awards to 15 organizations, chosen from nearly 450 applicants, under the MAHA ELEVATE model to test functional and lifestyle interventions that complement conventional care for people with Medicare. Every project includes a nutrition or physical activity component, and examples include dietitian coaching with home blood pressure monitoring that alerts clinicians remotely, and a virtual lifestyle program for obesity and hypertension, according to CMS. The agency said it plans a new funding notice for up to 15 more awards in 2027.
  • FYIEvidence Nov 20, 2026
    Primary careInternal medicine
    In a prespecified substudy of the open-label, randomized DANFLU-2 trial during the 2024-2025 season, respiratory and systemic symptom severity did not differ between adults 65 and older who developed laboratory-confirmed influenza after high-dose or standard-dose inactivated vaccine, the authors reported in Clinical Infectious Diseases. Of 1,273 analyzable home self-swabs, 121 were positive for influenza, 44 in the high-dose group and 77 in the standard-dose group. A post hoc analysis put the relative effectiveness of high-dose vaccine against laboratory-confirmed influenza at 42.2% (95% CI, 16.4% to 60.0%). The authors cited few breakthrough infections and incomplete questionnaires as limits, and four authors list Sanofi affiliations, according to the PubMed record.

Latest news

  1. Hospitals race to patch a critical Java flaw that researchers said AI helped them find in an hour and exploit in two more
  2. Childhood head CT was tied to about 1 extra brain tumor per 1,266 scans in a cohort of 3.7 million children
  3. A needle-free IV valve can stay open after disconnection, risking blood loss and air embolism, FDA warns

See all the latest news